You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

MITOXANTRONE HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Mitoxantrone Hydrochloride, and when can generic versions of Mitoxantrone Hydrochloride launch?

Mitoxantrone Hydrochloride is a drug marketed by Fresenius Kabi Oncol, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, and Rising. and is included in seven NDAs.

The generic ingredient in MITOXANTRONE HYDROCHLORIDE is mitoxantrone hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mitoxantrone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Mitoxantrone Hydrochloride

A generic version of MITOXANTRONE HYDROCHLORIDE was approved as mitoxantrone hydrochloride by FRESENIUS KABI USA on April 11th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MITOXANTRONE HYDROCHLORIDE?
  • What are the global sales for MITOXANTRONE HYDROCHLORIDE?
  • What is Average Wholesale Price for MITOXANTRONE HYDROCHLORIDE?
Drug patent expirations by year for MITOXANTRONE HYDROCHLORIDE
Recent Clinical Trials for MITOXANTRONE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Acute Leukemia French AssociationPhase 2
Cancer Institute and Hospital, Chinese Academy of Medical SciencesN/A
CSPC Ouyi Pharmaceutical Co., Ltd.N/A

See all MITOXANTRONE HYDROCHLORIDE clinical trials

Pharmacology for MITOXANTRONE HYDROCHLORIDE
Drug ClassTopoisomerase Inhibitor
Mechanism of ActionTopoisomerase Inhibitors
Medical Subject Heading (MeSH) Categories for MITOXANTRONE HYDROCHLORIDE

US Patents and Regulatory Information for MITOXANTRONE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Oncol MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 078606-001 May 14, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 078980-002 Apr 13, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 076611-001 Apr 11, 2006 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 077496-001 Apr 11, 2006 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hospira MITOXANTRONE HYDROCHLORIDE mitoxantrone hydrochloride INJECTABLE;INJECTION 076871-003 Apr 11, 2006 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.